AstraZeneca in Talks to Shift Coronavirus Vaccine Production to Catalent’s Maryland Factory
AstraZeneca is reportedly in talks to shift production of its coronavirus vaccine to a Maryland-based factory operated by Catalent, Inc.
The New York Times reported that the British drugmaker is in negotiations with the federal government to to retrofit a production line after embattled drugmaker Emergent BioSolutions was forced to stop manufacturing the vaccine at a plant in Baltimore.
AstraZeneca was awarded a $1.2 billion contract last May from the federal government for clinical trials and for production of 300 million doses of the vaccine.
A federal official told The Times that the government was negotiating its contract to shift production of the vaccine from Emergent to Catalent.
Catalent currently produces AstraZenca’s vaccine for export.
Holly Campbell, a spokeswoman for AstraZeneca told The Times “we can confirm we are working with Catalent but have not disclosed specific details on supply.” A spokesperson for Catalent declined to comment to the newspaper.
Click here to read more via The Hill.
Latest posts by BioBuzz Media (see all)
- Federal Realty Plans 10-Story Life Science Facility at Pike & Rose to Fuel Extension of Montgomery County’s Life Science and Biotech Corridor to North Bethesda - December 1, 2021
- BioHealth Capital Region Spotlight: Creative Bio-Peptides Awarded $5.78 from NIH to Develop Breakthrough Treatments for Neuroinflammatory/Neurodegenerative Indications - November 30, 2021
- IndyGeneUS AI, Inc. to Acquire the World’s First Blockchain-Mediated Free Market For Genetic Data, EncrypGen - November 29, 2021
- NeuExcell Therapeutics, Inc. Signs Lease with The Discovery Labs to Establish Corporate Headquarters in the Philadelphia Region - November 23, 2021
- Red Cell Forms Zephyr AI to Revolutionize Drug Discovery and Precision Medicine - November 23, 2021